Abstract
Relative biological effectiveness (RBE) is an important quantity in planning particle beam cancer therapy. In general, the RBE describes the biological effectiveness of a given primary beam with respect to a reference photon irradiation. RBE varies not only for different primary beams but also with depth in the target for a given beam modality. It is not a quantity that easily lends itself to measurements or computation as it depends on many biological and physical quantities. Numerous experiments in vitro using various cell lines and irradiation modalities have shown that a general relationship between RBE and the physical quantity Linear Energy Transfer (LET) exists. Several groups have proposed including LET in the radiation therapy treatment planning instead of the more complicated and elusive RBE. It has been shown that LET is an important quantity to consider in treating radio-resistant tumors. The concept of LET painting has been proposed with the goal of improving tumor control probability (TCP) for hypoxic tumors by focusing high LET radiation on the hypoxic region of the tumor while restricting the surrounding normal tissue to low LET radiation. In order to properly incorporate LET in clinical treatment, it is important to be able to experimentally measure and verify LET distribution. We propose a novel method for measuring LET using a dual chamber methodology exploiting the difference in the observed recombination between air filled ionization chambers (IC) and liquid filled ionization chambers (LIC). The resulting difference in the measured signals will be used to directly extract the relative LET of an actual treatment beam in real time. This paper describes our initial studies of this method, presents preliminary results, and discusses further improvements toward a practical real-time LET measuring device.
Highlights
The use of hadrons in radiation cancer therapy offers several advantages over traditional X-ray, gamma, and electron beams
We propose a novel method for measuring Linear Energy Transfer (LET) using a dual chamber methodology exploiting the difference in the observed recombination between air filled ionization chambers (IC) and liquid filled ionization chambers (LIC)
This is described by the quantity of Relative Biological Effectiveness (RBE)—the ratio of the physical dose using photons to the physical dose needed for a given beam modality to produce the same biological effect, for example 10% cell survival
Summary
The use of hadrons (protons or heavy ions) in radiation cancer therapy offers several advantages over traditional X-ray, gamma, and electron beams. Heavy charged particles exhibit a unique depth dose profile with low dose at the entrance of the patient, a distinct increase in the dose at the end of the range (i.e. Bragg peak) and minimal dose delivered beyond the Bragg peak This allows hadrons to deliver a highly conformal physical dose (i.e. energy deposited per unit mass) to deep-seated tumors with better sparing of nearby normal and critical structures than more conventional megavoltage photon beams. These physical advantages make hadron therapy attractive for modern cancer radiation therapy. Note that it has been widely recognized that even proton beams do not have a constant biological effectiveness along the beam path and that the enhanced biological effectiveness near the end of range should no longer be ignored for cases involving tumors in proximity to critical structures [1] [2]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Medical Physics, Clinical Engineering and Radiation Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.